CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 61 enrolled
Drug / intervention
Macrolane VRF30device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01331408
NCT01331408Phase 4Completed

An Open, Post-marketing, Multi-center Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks

Galderma R&D·interventional·Posted Apr 8, 2011·Updated Sep 28, 2022

In Brief

A Phase 4 clinical trial evaluating Macrolane VRF30 for Volume Restoration and Shaping of the Buttocks. Completed, enrolled 61 participants across 4 sites in 3 countries.

Detailed Summary

The purpose of the study is to evaluate the efficacy and safety of Macrolane for volume restoration and shaping of the buttocks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Spain, Sweden
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 8, 2011
Enrollment StartSep 1, 2008
Primary CompletionOct 1, 2009
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.2 years ago

Interventions

Macrolane VRF30device

Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject